Arthritis Experts to Gather, Funds on the Line
Published Date: 4/15/2025
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 3, 2025, open to the public both in person and online. They’ll discuss important updates and review grant applications, which could affect researchers and organizations seeking funding. If you want to join or share your thoughts, now’s the time to get ready—this meeting shapes future research and funding decisions!
Analyzed Economic Effects
5 provisions identified: 2 benefits, 1 costs, 2 mixed.
Closed Grant Review Session
On June 3, 2025, from 2:00 p.m. to 3:00 p.m., the council will close the meeting to review and evaluate grant applications. This closed session safeguards confidential trade secrets and personal information of applicants during grant evaluation.
Public Meeting — Virtual and In-Person
The National Institute of Arthritis and Musculoskeletal and Skin Diseases Advisory Council will hold a public meeting on June 3, 2025, with an open session from 9:30 a.m. to 1:15 p.m. You can attend in person at NIH Building 31, 31 Center Drive, Bethesda, MD 20892, or watch the videocast at https://videocast.nih.gov/watch=56710.
Opportunity to Submit Written Comments
Any interested person may file written comments by sending a statement (including name, address, phone, and affiliation when applicable) to the listed Contact Person. Submitting comments lets you share views that the Council may consider as it discusses research and funding matters.
On-Site Security and ID Requirements
Visitors attending the on-campus meeting must follow NIH security procedures, show one form of identification (for example, government photo ID, driver's license, or passport), and may have vehicles inspected before campus entry. These rules apply to anyone planning to attend in person.
Limited In-Person Seating; Request Accommodations
In-person attendance is limited to space available. If you need special assistance (for example, sign language interpretation) you must notify the Contact Person in advance to request reasonable accommodations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-06342, Submission for OMB Review; Comment Request
The Department of Defense wants to collect some info and needs the Office of Management and Budget’s thumbs-up first. This affects folks who provide data to the DoD and could change how and when they share it. Keep an eye out for deadlines and possible updates that might save time or tweak paperwork.
Next: 2025-06344, Agency Information Collection Activities: Information Collection Renewal; Comment Request; Community Reinvestment Act Qualifying Activities Confirmation Request Form
The OCC is renewing a form that banks use to confirm their community support activities under the Community Reinvestment Act. This renewal helps keep paperwork manageable and ensures banks keep showing how they help their communities. If you’re a bank or financial institution, now’s the time to check out the form and share your thoughts before the deadline!